These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 2668027

  • 1. Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas.
    Fehmann HC, Göke B, Göke R, Trautmann ME, Arnold R.
    FEBS Lett; 1989 Jul 31; 252(1-2):109-12. PubMed ID: 2668027
    [Abstract] [Full Text] [Related]

  • 2. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC, Göke R, Göke B, Bächle R, Wagner B, Arnold R.
    Biochim Biophys Acta; 1991 Feb 19; 1091(3):356-63. PubMed ID: 1705823
    [Abstract] [Full Text] [Related]

  • 3. Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Watanabe Y, Yamashita K.
    Metabolism; 1992 Apr 19; 41(4):359-63. PubMed ID: 1556941
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
    Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K.
    Diabetes; 1990 Nov 19; 39(11):1320-5. PubMed ID: 2146178
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.
    Diabetes Care; 1996 Aug 19; 19(8):857-63. PubMed ID: 8842604
    [Abstract] [Full Text] [Related]

  • 8. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC, Lavery KS, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Gault VA, Flatt PR.
    J Endocrinol; 2006 Oct 19; 191(1):93-100. PubMed ID: 17065392
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of galanin on islet cell secretory responses to VIP, GIP, 8-CCK, and glucagon by the perfused rat pancreas.
    Miralles P, Peiró E, Silvestre RA, Villanueva ML, Marco J.
    Metabolism; 1988 Aug 19; 37(8):766-70. PubMed ID: 2457142
    [Abstract] [Full Text] [Related]

  • 11. Effect of glucagon-like peptide-1 on insulin secretion.
    Shima K, Hirota M, Ohboshi C.
    Regul Pept; 1988 Aug 19; 22(3):245-52. PubMed ID: 3051138
    [Abstract] [Full Text] [Related]

  • 12. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB.
    Diabetes; 1998 Jul 19; 47(7):1046-52. PubMed ID: 9648827
    [Abstract] [Full Text] [Related]

  • 13. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness.
    Delmeire D, Flamez D, Moens K, Hinke SA, Van Schravendijk C, Pipeleers D, Schuit F.
    Biochem Pharmacol; 2004 Jul 01; 68(1):33-9. PubMed ID: 15183115
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F, Fehmann HC, Göke R, Göke B.
    Diabetes; 1995 Jan 01; 44(1):16-9. PubMed ID: 7813808
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR.
    Diabetologia; 2003 Feb 01; 46(2):222-30. PubMed ID: 12627321
    [Abstract] [Full Text] [Related]

  • 18. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion.
    Jia X, Brown JC, Ma P, Pederson RA, McIntosh CH.
    Am J Physiol; 1995 Apr 01; 268(4 Pt 1):E645-51. PubMed ID: 7733263
    [Abstract] [Full Text] [Related]

  • 19. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.
    Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CH.
    Diabetes; 1995 May 01; 44(5):495-500. PubMed ID: 7729605
    [Abstract] [Full Text] [Related]

  • 20. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr 01; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.